Article Details
Retrieved on: 2021-04-28 21:22:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Q4FY21 revenue grew 53% YoY to Rs 664 Crore, driven primarily by strong sales of our biosimilar insulins and monoclonal antibodies in key ...
Article found on: www.biospectrumindia.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here